The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
The real-time PCR-based test runs on the BD Max system and comes in a single tube that snaps into the BD MAX extraction cartridge.
The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
The École Polytechnique Fédérale de Lausanne's Samira Asgari uncovered rare variants that seem to govern an extreme response to RSV or HRV infection.
The test is the first of several planned CLIA-waived assays from Cepheid, and the first point-of-care test on the market to differentiate flu from RSV.
The Enigma MiniLab runs single-tube multiplex panels at the point of care, with a lower price point than other commercially available syndromic panel platforms.
The assay runs on the company's fully automated PCR-based Idylla platform and detects various strains of the flu virus and respiratory syncytial virus.
In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.
Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.
Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.
British researchers say they've been removed from EU grant applications, according to the Guardian.